{"id":"W3169007939","doi":"10.1200/jco.2021.39.15_suppl.2575","title":"CheckMate 8KX: Phase 1/2 multitumor preliminary analyses of a subcutaneous formulation of nivolumab (± rHuPH20).","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"Bristol-Myers Squibb Canada","keywords":"Medicine; Nivolumab; Immunogenicity; Internal medicine; Cancer; Oncology; Immunotherapy; Antibody; Immunology","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001234461,0.0008924587,0.0005868714,0.0004544953,0.000273883,0.0007810263,0.0009427503,0.0008329028,0.005389174],"category_scores_gemma":[0.0005664717,0.0003890896,0.0006318372,0.000284961,0.0004229753,0.00058554,0.0002900054,0.001812394,0.001019784],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001089106,"about_ca_system_score_gemma":0.001159531,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001499055,"about_ca_topic_score_gemma":0.003366053,"domain_scores_codex":[0.9996991,0.0001240809,0.00001182827,0.00005090943,0.00005573414,0.0000583954],"domain_scores_gemma":[0.9996598,0.00004925442,0.00008151152,0.00004099106,0.0000355113,0.0001330025],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.1866673,0.1066747,0.008835469,0.001576316,0.001079874,0.0006335396,0.00055346,0.01003449,0.4870197,0.001208953,0.02024136,0.175475],"study_design_scores_gemma":[0.1783597,0.6389917,0.02835628,0.0001154125,0.0007664613,0.001798884,0.0001597148,0.00855047,0.1104078,0.0004841697,0.03193118,0.00007824536],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9857103,0.001616642,0.001824657,0.0003247504,0.0001011517,0.003418108,0.002802444,0.0002286963,0.003973152],"genre_scores_gemma":[0.9797969,0.001312387,0.003442955,0.0006030825,0.00005347045,0.002289706,0.006371232,0.00009465357,0.006035536],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.005389174,"threshold_uncertainty_score":0.01802862,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.213878784693764,"score_gpt":0.5434117586399005,"score_spread":0.3295329739461365,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}